8STN Stock Overview
Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Sorrento Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.30 |
| 52 Week High | US$2.79 |
| 52 Week Low | US$0.13 |
| Beta | 2.12 |
| 11 Month Change | 0% |
| 3 Month Change | 19.20% |
| 1 Year Change | -80.28% |
| 33 Year Change | -91.94% |
| 5 Year Change | -95.22% |
| Change since IPO | -94.92% |
Recent News & Updates
Recent updates
Shareholder Returns
| 8STN | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -1.1% | 1.1% |
| 1Y | -80.3% | -18.8% | 7.2% |
Return vs Industry: 8STN underperformed the German Biotechs industry which returned -23.1% over the past year.
Return vs Market: 8STN underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| 8STN volatility | |
|---|---|
| 8STN Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 8STN's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 8STN's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 949 | Henry Ji | www.sorrentotherapeutics.com |
Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system.
Sorrento Therapeutics, Inc. Fundamentals Summary
| 8STN fundamental statistics | |
|---|---|
| Market cap | €154.45m |
| Earnings (TTM) | -€626.04m |
| Revenue (TTM) | €56.58m |
2.7x
P/S Ratio-0.2x
P/E RatioIs 8STN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8STN income statement (TTM) | |
|---|---|
| Revenue | US$60.71m |
| Cost of Revenue | US$233.93m |
| Gross Profit | -US$173.23m |
| Other Expenses | US$498.42m |
| Earnings | -US$671.64m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.24 |
| Gross Margin | -285.36% |
| Net Profit Margin | -1,106.41% |
| Debt/Equity Ratio | -55.7% |
How did 8STN perform over the long term?
See historical performance and comparison